Preventing coronary heart disease in the managed care era: Improving the cost effectiveness of lipid-lowering therapy with HMG-CoA reductase inhibitors

American Journal of Managed Care

Volumn 3, Issue 9 SUPPL. 1, 1997, Pages

  Jacobson, Terry A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001900812     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Grundy SM, Chait A, Clark LT, et al, for the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP). JAMA 1993;269:3015-3023.
2. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-V). Arch Intern Med 1993;153:154-164.
3. American Heart Association. 1997 Heart and Stroke Statistica/ Update. Dallas, TX: American Heart Association, 1996.
4. Pedersen TR, Kjekshus J, Berg K, et al, for the Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
5. Shepherd J, Cobbe S, Ford I, et al, for the West of Scotland Coronary Prevention Study (WOSCOPS) Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333;1301-1307.
6. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events (CARE) Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
7. Goldman L, Garber AM, Grover SA, Hlatky MA. Task Force 6. Cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996;27:1020-1030.
8. Tsevat J, Duke D, Goldman L, Pfeffer MA. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol 1995;26:914-919.
9. Eisenberg JM. Clinical economics: A guide to economic analysis of clinical practices. JAMA 1989;262:2879-2886.
10. Kinosian BP, Eisenberg JM. Cutting into cholesterol: Cost-effective alternatives for treating hypercholesterolemia. JAMA 1988; 259:2249-2254.
11. Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs: Cost effectiveness of pharmacologic management. JAMA 1990;264: 2249-2254.
12. Martens LL, Rutten FFH, Erkelens W, Ascoop CAPL. Clinical benefits and cost effectiveness of lowering serum cholesterol levels: The case of simvastatin and cholestyramine in The Netherlands. Am J Cardiol 1990;65(Suppl):27F-32F.
13. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991;265:1145-1151.
14. Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: Estimating the benefits of increasing HDL-C. JAMA 1995;273: 1032-1038.
15. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources: Results of the Scandinavian Simvastatin Survival Study. Circulation 1996;93:1796-1802.
16. Johanneson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H, for the Scandinavian Simvastatin Survival Study Group. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997;336:332-336.
17. Epstein RS, Garrahan S, Nelsen L, et al. The cholesterol population model: US population requirements for treatment of hypercholesterolemia. Am J Man Care 1996;2: 1362-1370.
18. Sempos CT, Cleeman JL, Carroll MD, et al. Prevalence of high blood cholesterol among US adults: An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA 1993;269: 3009-3014.
19. Nash DT. Meeting national cholesterol education goals in clinical practice - A comparison of lovastatin and fluvastatin in primary prevention. Am J Cardiol 1996;78 (Suppl 6A):26-31.
20. Martens LL, Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: Comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Therapeutics 1994;16: 1052-1062.
21. Red Book Update. Montvale, NJ: Medical Economics Co. January, 1997.
22. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996;275:128-133.
23. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-682.
24. Ashraf T, Hay JW, Pitt B, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996;78:409-414.
25. Wittels EH, Hay JW, Gotto AM Jr. Medical costs of coronary artery disease in the United States. Am J Cardiol 1990;65:432-440.
26. Shepherd J, Cobbe S, Ford I, et al, for the West of Scotland Coronary Prevention Study (WOSCOPS) Economic Analysis Group. The cost-effectiveness of preventing initial coronary events with pravastatin. Results of the West of Scotland Coronary Prevention Study Economic Analysis. J Amer Coll Cardiol 1997;29(Suppl A):Abstract #968-54 (168A).
27. Jacobson TA. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era. Am J Cardiol 1996; 78(Suppl 6A);32-41.